Plerixafor was recently successfully used at lower doses in 6-month intervals in patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic disease defined by gain-of-function mutations in CXCR4 (58, 59). This evidence concerns the gene CXCR4 and WHIM syndrome.